Although nucleotide analogs (NAs) and interferons are currently the primary treatments for chronic hepatitis B, they do not entirely remove cccDNA from hepatocytes. Antiviral therapy's desired outcome is the absence of hepatitis B surface antigen(HBsAg), often known as a clinical cure. Although interferon therapy has significantly higher HBsAg clearance and serologic conversion rates than NAs, combination or sequential therapy can improve HBsAg clearance and serologic conversion rates to some extent. Still, only a small proportion of patients will achieve clinical cure. As a result, it is critical to explore indications that might predict clinical cure before and during antiviral medication, allowing for early and prompt identification of patients more likely to achieve HBsAg clearance, improving clinical cure rates, and reducing treatment expenses. In this paper, we review the progress of recent studies on predictors of clinical cure in chronic hepatitis B, and discuss their value in predicting clinical cure to provide a reference for optimizing CHB treatment strategy.